Full-Time

Research Scientist

Posted on 3/28/2023

AbCellera Biologics

AbCellera Biologics

501-1,000 employees

Accelerates antibody drug discovery with data science

Data & Analytics
AI & Machine Learning
Biotechnology

Senior

Vancouver, BC, Canada

Required Skills
Python
Communications
Requirements
  • You can contribute to the design, execution, and evaluation of in-silico protein engineering workflows
  • You are excited about the opportunity to integrate high throughput protein engineering methods with in-silico tools to solve real-world drug discovery problems
  • You are enthusiastic about applying your expertise in protein engineering to improve the speed and quality of protein biotherapeutics development
  • You are strongly self-motivated and work independently to identify project needs and follow that up with building and implementing solutions
  • A PhD in Biochemistry, Biophysics, Structural Biology, Computational Biology, Computer Science, or a related field, or MSc with 5+ years of related experience in a biological research setting
  • A comprehensive understanding of techniques to perform in-silico protein structure design using tools such as Rosetta software suite
  • Working knowledge of antibody structure and function
  • Excellent programming skills (Python preferred)
  • Familiarity with techniques applicable to the molecular design, engineering, and experimental evaluation of antibody and/or antigen libraries for protein engineering purposes
  • Strong interpersonal skills with the ability to work collaboratively as a member of cross-functional team
  • Excellent verbal and written communication skills, including public presentation of complex data

AbCellera stands out as a leader in the biotech industry due to its unique approach to antibody drug discovery, combining expert teams, advanced technology, and data science to expedite the process from target to clinic across various therapeutic areas. The company's competitive edge lies in its ability to enable swift progress, cost reduction, and problem-solving in drug development for both innovative biotechs and leading pharmaceutical companies. Furthermore, AbCellera's commitment to technical innovation is evident in its recent presentation of new data on two T-Cell Engager Programs at SITC 2023, demonstrating its active role in advancing the field.

Company Stage

Series A

Total Funding

$393.1M

Headquarters

Vancouver, Canada

Founded

2012

Growth & Insights
Headcount

6 month growth

-3%

1 year growth

16%

2 year growth

76%
INACTIVE